ID   PIAS4_HUMAN             Reviewed;         510 AA.
AC   Q8N2W9; O75926; Q96G19; Q9UN16;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2002, sequence version 1.
DT   12-SEP-2018, entry version 164.
DE   RecName: Full=E3 SUMO-protein ligase PIAS4;
DE            EC=2.3.2.27;
DE   AltName: Full=PIASy;
DE   AltName: Full=Protein inhibitor of activated STAT protein 4;
DE   AltName: Full=Protein inhibitor of activated STAT protein gamma;
DE            Short=PIAS-gamma;
DE   AltName: Full=RING-type E3 ubiquitin transferase PIAS4 {ECO:0000305};
GN   Name=PIAS4; Synonyms=PIASG;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAH29874.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=B-cell;
RX   PubMed=9724754; DOI=10.1073/pnas.95.18.10626;
RA   Liu B., Liao J., Rao X., Kushner S.A., Chung C.D., Chang D.D.,
RA   Shuai K.;
RT   "Inhibition of Stat1-mediated gene activation by PIAS1.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:10626-10631(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain, Lung, and Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 10-510, AND INTERACTION WITH TP53.
RX   PubMed=11388671; DOI=10.1023/A:1011392811628;
RA   Nelson V., Davis G.E., Maxwell S.A.;
RT   "A putative protein inhibitor of activated STAT (PIASy) interacts with
RT   p53 and inhibits p53-mediated transactivation but not apoptosis.";
RL   Apoptosis 6:221-234(2001).
RN   [4] {ECO:0000305}
RP   INTERACTION WITH STAT1, SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   23-LEU-LEU-24.
RX   PubMed=11248056; DOI=10.1073/pnas.051489598;
RA   Liu B., Gross M., ten Hoeve J., Shuai K.;
RT   "A transcriptional corepressor of Stat1 with an essential LXXLL
RT   signature motif.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:3203-3207(2001).
RN   [5]
RP   INTERACTION WITH AR, TISSUE SPECIFICITY, AND MUTAGENESIS OF
RP   23-LEU-LEU-24.
RX   PubMed=11439351; DOI=10.1038/sj.onc.1204489;
RA   Gross M., Liu B., Tan J.-A., French F.S., Carey M., Shuai K.;
RT   "Distinct effects of PIAS proteins on androgen-mediated gene
RT   activation in prostate cancer cells.";
RL   Oncogene 20:3880-3887(2001).
RN   [6]
RP   INTERACTION WITH AXIN1.
RX   PubMed=12223491; DOI=10.1074/jbc.M208099200;
RA   Rui H.L., Fan E., Zhou H.M., Xu Z., Zhang Y., Lin S.C.;
RT   "SUMO-1 modification of the C-terminal KVEKVD of Axin is required for
RT   JNK activation but has no effect on Wnt signaling.";
RL   J. Biol. Chem. 277:42981-42986(2002).
RN   [7]
RP   INTERACTION WITH GATA2.
RX   PubMed=12750312; DOI=10.1161/01.RES.0000076893.70898.36;
RA   Chun T.-H., Itoh H., Subramanian L., Iniguez-Lluhi J.A., Nakao K.;
RT   "Modification of GATA-2 transcriptional activity in endothelial cells
RT   by the SUMO E3 ligase PIASy.";
RL   Circ. Res. 92:1201-1208(2003).
RN   [8]
RP   FUNCTION IN SUMOYLATION OF TCF4, SUBCELLULAR LOCATION, AND MUTAGENESIS
RP   OF LYS-35 AND LYS-128.
RX   PubMed=12727872; DOI=10.1093/emboj/cdg204;
RA   Yamamoto H., Ihara M., Matsuura Y., Kikuchi A.;
RT   "Sumoylation is involved in beta-catenin-dependent activation of Tcf-
RT   4.";
RL   EMBO J. 22:2047-2059(2003).
RN   [9]
RP   FUNCTION IN SUMOYLATION OF MYB.
RX   PubMed=12631292; DOI=10.1046/j.1432-1033.2003.03504.x;
RA   Dahle O., Andersen T.O., Nordgaard O., Matre V., Del Sal G.,
RA   Gabrielsen O.S.;
RT   "Transactivation properties of c-Myb are critically dependent on two
RT   SUMO-1 acceptor sites that are conjugated in a PIASy enhanced
RT   manner.";
RL   Eur. J. Biochem. 270:1338-1348(2003).
RN   [10]
RP   FUNCTION IN SUMOYLATION OF CEBPA.
RX   PubMed=12511558; DOI=10.1074/jbc.M210440200;
RA   Subramanian L., Benson M.D., Iniguez-Lluhi J.A.;
RT   "A synergy control motif within the attenuator domain of
RT   CCAAT/enhancer-binding protein alpha inhibits transcriptional synergy
RT   through its PIASy-enhanced modification by SUMO-1 or SUMO-3.";
RL   J. Biol. Chem. 278:9134-9141(2003).
RN   [11]
RP   INTERACTION WITH TICAM1.
RX   PubMed=15251447; DOI=10.1016/j.febslet.2004.05.081;
RA   Zhang J., Xu L.G., Han K.J., Wei X., Shu H.B.;
RT   "PIASy represses TRIF-induced ISRE and NF-kappaB activation but not
RT   apoptosis.";
RL   FEBS Lett. 570:97-101(2004).
RN   [12]
RP   SUMOYLATION AT LYS-35 AND LYS-128, FUNCTION IN SUMOYLATION OF TCF4,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-35 AND LYS-128.
RX   PubMed=15831457; DOI=10.1128/MCB.25.9.3506-3518.2005;
RA   Ihara M., Yamamoto H., Kikuchi A.;
RT   "SUMO-1 modification of PIASy, an E3 ligase, is necessary for PIASy-
RT   dependent activation of Tcf-4.";
RL   Mol. Cell. Biol. 25:3506-3518(2005).
RN   [13]
RP   FUNCTION IN SUMOYLATION OF PARK7.
RX   PubMed=15976810; DOI=10.1038/sj.cdd.4401704;
RA   Shinbo Y., Niki T., Taira T., Ooe H., Takahashi-Niki K., Maita C.,
RA   Seino C., Iguchi-Ariga S.M.M., Ariga H.;
RT   "Proper SUMO-1 conjugation is essential to DJ-1 to exert its full
RT   activities.";
RL   Cell Death Differ. 13:96-108(2006).
RN   [14]
RP   INTERACTION WITH KLF8.
RX   PubMed=16617055; DOI=10.1074/jbc.M513135200;
RA   Wei H., Wang X., Gan B., Urvalek A.M., Melkoumian Z.K., Guan J.-L.,
RA   Zhao J.;
RT   "Sumoylation delimits KLF8 transcriptional activity associated with
RT   the cell cycle regulation.";
RL   J. Biol. Chem. 281:16664-16671(2006).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-114, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [17]
RP   FUNCTION, AND INTERACTION WITH MTA1.
RX   PubMed=21965678; DOI=10.1074/jbc.M111.267237;
RA   Cong L., Pakala S.B., Ohshiro K., Li D.Q., Kumar R.;
RT   "SUMOylation and SUMO-interacting motif (SIM) of metastasis tumor
RT   antigen 1 (MTA1) synergistically regulate its transcriptional
RT   repressor function.";
RL   J. Biol. Chem. 286:43793-43808(2011).
RN   [18]
RP   FUNCTION IN SUMOYLATION OF HERC2 AND RNF168.
RX   PubMed=22508508; DOI=10.1083/jcb.201106152;
RA   Danielsen J.R., Povlsen L.K., Villumsen B.H., Streicher W.,
RA   Nilsson J., Wikstrom M., Bekker-Jensen S., Mailand N.;
RT   "DNA damage-inducible SUMOylation of HERC2 promotes RNF8 binding via a
RT   novel SUMO-binding Zinc finger.";
RL   J. Cell Biol. 197:179-187(2012).
RN   [19]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-59, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [20]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-9; LYS-35; LYS-56; LYS-59;
RP   LYS-68; LYS-69 AND LYS-125, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-
RT   modification with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
CC   -!- FUNCTION: Functions as an E3-type small ubiquitin-like modifier
CC       (SUMO) ligase, stabilizing the interaction between UBE2I and the
CC       substrate, and as a SUMO-tethering factor. Plays a crucial role as
CC       a transcriptional coregulation in various cellular pathways,
CC       including the STAT pathway, the p53/TP53 pathway, the Wnt pathway
CC       and the steroid hormone signaling pathway. Involved in gene
CC       silencing. Mediates sumoylation of CEBPA, PARK7, HERC2, MYB, TCF4
CC       and RNF168. In Wnt signaling, represses LEF1 and enhances TCF4
CC       transcriptional activities through promoting their sumoylations.
CC       Enhances the sumoylation of MTA1 and may participate in its
CC       paralog-selective sumoylation. {ECO:0000269|PubMed:12511558,
CC       ECO:0000269|PubMed:12631292, ECO:0000269|PubMed:12727872,
CC       ECO:0000269|PubMed:15831457, ECO:0000269|PubMed:15976810,
CC       ECO:0000269|PubMed:21965678, ECO:0000269|PubMed:22508508}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Interacts with AR, AXIN1, GATA2, LEF1, TP53 and STAT1
CC       (IFNG-induced). Binds to AT-rich DNA sequences, known as matrix or
CC       scaffold attachment regions (MARs/SARs) (By similarity). Interacts
CC       with TICAM1. Interacts with KLF8; the interaction results in SUMO
CC       ligation and repression of KLF8 transcriptional activity and of
CC       its cell cycle progression into G(1) phase. Interacts with MTA1.
CC       {ECO:0000250, ECO:0000269|PubMed:11248056,
CC       ECO:0000269|PubMed:11388671, ECO:0000269|PubMed:11439351,
CC       ECO:0000269|PubMed:12223491, ECO:0000269|PubMed:12750312,
CC       ECO:0000269|PubMed:15251447, ECO:0000269|PubMed:16617055,
CC       ECO:0000269|PubMed:21965678}.
CC   -!- INTERACTION:
CC       P11474:ESRRA; NbExp=3; IntAct=EBI-473160, EBI-372412;
CC       Q16665:HIF1A; NbExp=3; IntAct=EBI-473160, EBI-447269;
CC       P42858:HTT; NbExp=3; IntAct=EBI-473160, EBI-466029;
CC       P09874:PARP1; NbExp=5; IntAct=EBI-473160, EBI-355676;
CC       Q04206:RELA; NbExp=2; IntAct=EBI-473160, EBI-73886;
CC       P61956:SUMO2; NbExp=3; IntAct=EBI-473160, EBI-473220;
CC       O75528:TADA3; NbExp=2; IntAct=EBI-473160, EBI-473249;
CC       P04637:TP53; NbExp=2; IntAct=EBI-473160, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body
CC       {ECO:0000269|PubMed:11248056, ECO:0000269|PubMed:12727872,
CC       ECO:0000269|PubMed:15831457}. Note=Colocalizes with SUMO1 and
CC       TCF7L2/TCF4 and LEF1 in a subset of PML (promyelocytic leukemia)
CC       nuclear bodies.
CC   -!- TISSUE SPECIFICITY: Highly expressed in testis and, at lower
CC       levels, in spleen, prostate, ovary, colon and peripheral blood
CC       leukocytes. {ECO:0000269|PubMed:11439351}.
CC   -!- DOMAIN: The LXXLL motif is a coregulator signature that is
CC       essential for transcriptional corepression.
CC   -!- PTM: Sumoylated. Lys-35 is the main site of sumoylation.
CC       Sumoylation is required for TCF4 sumoylation and transcriptional
CC       activation. Represses LEF1 transcriptional activity. SUMO1 is the
CC       preferred conjugate. {ECO:0000269|PubMed:15831457}.
CC   -!- SIMILARITY: Belongs to the PIAS family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD45155.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AF077952; AAC36703.1; -; mRNA.
DR   EMBL; BC010047; AAH10047.2; -; mRNA.
DR   EMBL; BC029874; AAH29874.1; -; mRNA.
DR   EMBL; BC066895; AAH66895.1; -; mRNA.
DR   EMBL; AF164437; AAD45155.1; ALT_INIT; mRNA.
DR   CCDS; CCDS12118.1; -.
DR   RefSeq; NP_056981.2; NM_015897.3.
DR   UniGene; Hs.105779; -.
DR   ProteinModelPortal; Q8N2W9; -.
DR   SMR; Q8N2W9; -.
DR   BioGrid; 119624; 129.
DR   DIP; DIP-32499N; -.
DR   ELM; Q8N2W9; -.
DR   IntAct; Q8N2W9; 65.
DR   MINT; Q8N2W9; -.
DR   STRING; 9606.ENSP00000262971; -.
DR   iPTMnet; Q8N2W9; -.
DR   PhosphoSitePlus; Q8N2W9; -.
DR   BioMuta; PIAS4; -.
DR   DMDM; 34922831; -.
DR   EPD; Q8N2W9; -.
DR   MaxQB; Q8N2W9; -.
DR   PaxDb; Q8N2W9; -.
DR   PeptideAtlas; Q8N2W9; -.
DR   PRIDE; Q8N2W9; -.
DR   ProteomicsDB; 71739; -.
DR   DNASU; 51588; -.
DR   Ensembl; ENST00000262971; ENSP00000262971; ENSG00000105229.
DR   GeneID; 51588; -.
DR   KEGG; hsa:51588; -.
DR   UCSC; uc002lzg.4; human.
DR   CTD; 51588; -.
DR   DisGeNET; 51588; -.
DR   EuPathDB; HostDB:ENSG00000105229.6; -.
DR   GeneCards; PIAS4; -.
DR   HGNC; HGNC:17002; PIAS4.
DR   HPA; HPA010598; -.
DR   MIM; 605989; gene.
DR   neXtProt; NX_Q8N2W9; -.
DR   OpenTargets; ENSG00000105229; -.
DR   PharmGKB; PA134945903; -.
DR   eggNOG; KOG2169; Eukaryota.
DR   eggNOG; ENOG410XQ2E; LUCA.
DR   GeneTree; ENSGT00550000074410; -.
DR   HOGENOM; HOG000230594; -.
DR   HOVERGEN; HBG053598; -.
DR   InParanoid; Q8N2W9; -.
DR   KO; K16065; -.
DR   OMA; LRICYTD; -.
DR   OrthoDB; EOG091G08G5; -.
DR   PhylomeDB; Q8N2W9; -.
DR   TreeFam; TF323787; -.
DR   Reactome; R-HSA-196791; Vitamin D (calciferol) metabolism.
DR   Reactome; R-HSA-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-HSA-3232118; SUMOylation of transcription factors.
DR   Reactome; R-HSA-3232142; SUMOylation of ubiquitinylation proteins.
DR   Reactome; R-HSA-3899300; SUMOylation of transcription cofactors.
DR   Reactome; R-HSA-4085377; SUMOylation of SUMOylation proteins.
DR   Reactome; R-HSA-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-HSA-4615885; SUMOylation of DNA replication proteins.
DR   Reactome; R-HSA-4755510; SUMOylation of immune response proteins.
DR   Reactome; R-HSA-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-HSA-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-HSA-5693607; Processing of DNA double-strand break ends.
DR   Reactome; R-HSA-69473; G2/M DNA damage checkpoint.
DR   SignaLink; Q8N2W9; -.
DR   SIGNOR; Q8N2W9; -.
DR   UniPathway; UPA00886; -.
DR   ChiTaRS; PIAS4; human.
DR   GeneWiki; PIAS4; -.
DR   GenomeRNAi; 51588; -.
DR   PRO; PR:Q8N2W9; -.
DR   Proteomes; UP000005640; Chromosome 19.
DR   Bgee; ENSG00000105229; Expressed in 182 organ(s), highest expression level in testis.
DR   CleanEx; HS_PIAS4; -.
DR   Genevisible; Q8N2W9; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:BHF-UCL.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:1990234; C:transferase complex; IEA:Ensembl.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0008022; F:protein C-terminus binding; IEA:Ensembl.
DR   GO; GO:0061665; F:SUMO ligase activity; IDA:BHF-UCL.
DR   GO; GO:0019789; F:SUMO transferase activity; IMP:UniProtKB.
DR   GO; GO:0003714; F:transcription corepressor activity; IEA:Ensembl.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; NAS:UniProtKB.
DR   GO; GO:0006303; P:double-strand break repair via nonhomologous end joining; TAS:Reactome.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IDA:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IEA:Ensembl.
DR   GO; GO:1902231; P:positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IEA:Ensembl.
DR   GO; GO:1902174; P:positive regulation of keratinocyte apoptotic process; ISS:BHF-UCL.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; IDA:UniProtKB.
DR   GO; GO:0016925; P:protein sumoylation; IDA:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0042359; P:vitamin D metabolic process; TAS:Reactome.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.720.30; -; 1.
DR   Gene3D; 2.60.120.780; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR027224; PIAS4.
DR   InterPro; IPR023321; PINIT.
DR   InterPro; IPR038654; PINIT_sf.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   InterPro; IPR004181; Znf_MIZ.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10782:SF9; PTHR10782:SF9; 1.
DR   Pfam; PF14324; PINIT; 1.
DR   Pfam; PF02891; zf-MIZ; 1.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51466; PINIT; 1.
DR   PROSITE; PS50800; SAP; 1.
DR   PROSITE; PS51044; ZF_SP_RING; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; DNA-binding; Isopeptide bond;
KW   Metal-binding; Nucleus; Reference proteome; Repressor; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation;
KW   Ubl conjugation pathway; Wnt signaling pathway; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330}.
FT   CHAIN         2    510       E3 SUMO-protein ligase PIAS4.
FT                                /FTId=PRO_0000218982.
FT   DOMAIN       12     46       SAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00186, ECO:0000305}.
FT   DOMAIN      119    279       PINIT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00799}.
FT   ZN_FING     311    388       SP-RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00452}.
FT   MOTIF        20     24       LXXLL motif.
FT   COMPBIAS    464    492       Asp/Glu-rich (acidic).
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330}.
FT   MOD_RES     114    114       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   CROSSLNK      9      9       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK     35     35       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate.
FT   CROSSLNK     35     35       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate. {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK     56     56       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK     59     59       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25218447,
FT                                ECO:0000244|PubMed:28112733}.
FT   CROSSLNK     68     68       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK     69     69       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    125    125       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:28112733}.
FT   CROSSLNK    128    128       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT   MUTAGEN      23     24       LL->AA: Loss of repression of AR- and
FT                                STAT1-induced transcription; no effect on
FT                                AR- and STAT1-binding.
FT                                {ECO:0000269|PubMed:11248056,
FT                                ECO:0000269|PubMed:11439351}.
FT   MUTAGEN      35     35       K->R: Complete loss of sumoylation. No
FT                                enhancement of TCF4 sumoylation. No
FT                                effect on interaction with TCF4.
FT                                Colocalizes with SUMO1 in nucleus but
FT                                concentrated into nuclear granules.
FT                                {ECO:0000269|PubMed:12727872,
FT                                ECO:0000269|PubMed:15831457}.
FT   MUTAGEN     128    128       K->R: Some loss of sumoylation.
FT                                {ECO:0000269|PubMed:12727872,
FT                                ECO:0000269|PubMed:15831457}.
FT   MUTAGEN     342    342       C->A: Inhibits TCF4 sumoylation. Inhibits
FT                                beta-catenin-mediated TCF7L2/TCF4
FT                                activity. No colocalization with
FT                                TCF7L2/TCF4 in nuclear punctate
FT                                structures; when associated with A-347.
FT   MUTAGEN     347    347       C->A: Inhibits TCF4 sumoylation. Inhibits
FT                                beta-catenin-mediated TCF7L2/TCF4
FT                                activity. No colocalization with
FT                                TCF7L2/TCF4 in nuclear punctate
FT                                structures; when associated with A-342.
FT                                AR- and STAT1-binding.
FT   CONFLICT    178    178       N -> K (in Ref. 1). {ECO:0000305}.
FT   CONFLICT    179    182       SREL -> FQGM (in Ref. 1 and 3).
FT                                {ECO:0000305}.
FT   CONFLICT    482    482       E -> G (in Ref. 2; AAH66895).
FT                                {ECO:0000305}.
SQ   SEQUENCE   510 AA;  56504 MW;  26AAA18246E1ACE3 CRC64;
     MAAELVEAKN MVMSFRVSDL QMLLGFVGRS KSGLKHELVT RALQLVQFDC SPELFKKIKE
     LYETRYAKKN SEPAPQPHRP LDPLTMHSTY DRAGAVPRTP LAGPNIDYPV LYGKYLNGLG
     RLPAKTLKPE VRLVKLPFFN MLDELLKPTE LVPQNNEKLQ ESPCIFALTP RQVELIRNSR
     ELQPGVKAVQ VVLRICYSDT SCPQEDQYPP NIAVKVNHSY CSVPGYYPSN KPGVEPKRPC
     RPINLTHLMY LSSATNRITV TWGNYGKSYS VALYLVRQLT SSELLQRLKT IGVKHPELCK
     ALVKEKLRLD PDSEIATTGV RVSLICPLVK MRLSVPCRAE TCAHLQCFDA VFYLQMNEKK
     PTWMCPVCDK PAPYDQLIID GLLSKILSEC EDADEIEYLV DGSWCPIRAE KERSCSPQGA
     ILVLGPSDAN GLLPAPSVNG SGALGSTGGG GPVGSMENGK PGADVVDLTL DSSSSSEDEE
     EEEEEEEDED EEGPRPKRRC PFQKGLVPAC
//
ID   PIAS4_MOUSE             Reviewed;         507 AA.
AC   Q9JM05; Q8R165;
DT   19-SEP-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 2.
DT   12-SEP-2018, entry version 159.
DE   RecName: Full=E3 SUMO-protein ligase PIAS4;
DE            EC=2.3.2.27;
DE   AltName: Full=PIASy;
DE   AltName: Full=Protein inhibitor of activated STAT protein 4;
DE   AltName: Full=Protein inhibitor of activated STAT protein gamma;
DE            Short=PIAS-gamma;
DE   AltName: Full=RING-type E3 ubiquitin transferase PIAS4 {ECO:0000305};
GN   Name=Pias4; Synonyms=Piasg;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090 {ECO:0000312|EMBL:AAF72040.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA], TISSUE SPECIFICITY, AND DEVELOPMENTAL
RP   STAGE.
RC   TISSUE=Brain;
RX   PubMed=10854042; DOI=10.1385/JMN:14:1-2:107;
RA   Sturm S., Koch M., White F.A.;
RT   "Cloning and analysis of a murine Pias family member, Pias-gamma, in
RT   developing skin and neurons.";
RL   J. Mol. Neurosci. 14:107-121(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3] {ECO:0000305}
RP   INTERACTION WITH LEF1, DNA-BINDING, SUMOYLATION, SUBCELLULAR LOCATION,
RP   AND MUTAGENESIS OF CYS-330; CYS-335; HIS-337; CYS-340 AND
RP   470-SER--SER-474.
RX   PubMed=11731474; DOI=10.1101/gad.944801;
RA   Sachdev S., Bruhn L., Sieber H., Pichler A., Melchior F.,
RA   Grosschedl R.;
RT   "PIASy, a nuclear matrix-associated SUMO E3 ligase, represses LEF1
RT   activity by sequestration into nuclear bodies.";
RL   Genes Dev. 15:3088-3103(2001).
RN   [4]
RP   TISSUE SPECIFICITY.
RX   PubMed=12750312; DOI=10.1161/01.RES.0000076893.70898.36;
RA   Chun T.-H., Itoh H., Subramanian L., Iniguez-Lluhi J.A., Nakao K.;
RT   "Modification of GATA-2 transcriptional activity in endothelial cells
RT   by the SUMO E3 ligase PIASy.";
RL   Circ. Res. 92:1201-1208(2003).
RN   [5]
RP   SUBCELLULAR LOCATION, INTERACTION WITH TRIM32, AND UBIQUITINATION.
RX   PubMed=16816390; DOI=10.1074/jbc.M601655200;
RA   Albor A., El-Hizawi S., Horn E.J., Laederich M., Frosk P.,
RA   Wrogemann K., Kulesz-Martin M.;
RT   "The interaction of Piasy with Trim32, an E3-ubiquitin ligase mutated
RT   in limb-girdle muscular dystrophy type 2H, promotes Piasy degradation
RT   and regulates UVB-induced keratinocyte apoptosis through NFkappaB.";
RL   J. Biol. Chem. 281:25850-25866(2006).
RN   [6]
RP   INTERACTION WITH MOMLV CA.
RX   PubMed=16352559; DOI=10.1128/JVI.80.1.342-352.2006;
RA   Yueh A., Leung J., Bhattacharyya S., Perrone L.A., de los Santos K.,
RA   Pu S.-Y., Goff S.P.;
RT   "Interaction of moloney murine leukemia virus capsid with Ubc9 and
RT   PIASy mediates SUMO-1 addition required early in infection.";
RL   J. Virol. 80:342-352(2006).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and
RT   expression.";
RL   Cell 143:1174-1189(2010).
CC   -!- FUNCTION: Functions as an E3-type small ubiquitin-like modifier
CC       (SUMO) ligase, stabilizing the interaction between UBE2I and the
CC       substrate, and as a SUMO-tethering factor. Plays a crucial role as
CC       a transcriptional coregulation in various cellular pathways,
CC       including the STAT pathway, the p53/TP53 pathway, the Wnt pathway
CC       and the steroid hormone signaling pathway. Involved in gene
CC       silencing. Mediates sumoylation of CEBPA, PARK7, HERC2, MYB, TCF4
CC       and RNF168. In Wnt signaling, represses LEF1 and enhances TCF4
CC       transcriptional activities through promoting their sumoylations.
CC       Enhances the sumoylation of MTA1 and may participate in its
CC       paralog-selective sumoylation (By similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine.
CC   -!- PATHWAY: Protein modification; protein sumoylation.
CC   -!- SUBUNIT: Interacts with AR, AXIN1, GATA2, LEF1, TP53 and STAT1,
CC       after treatment with IFNG. Binds to AT-rich DNA sequences, known
CC       as matrix or scaffold attachment regions (MARs/SARs) (By
CC       similarity). Interacts with TICAM1 (By similarity). Interacts with
CC       Moloney murine leukemia virus CA. Interacts with KLF8; the
CC       interaction results in SUMO ligation and repression of KLF8
CC       transcriptional activity and of its cell cycle progression into
CC       G(1) phase. Interacts with MTA1 (By similarity). Interacts with
CC       TRIM32 upon treatment with UVB and TNF-alpha. {ECO:0000250,
CC       ECO:0000269|PubMed:11731474, ECO:0000269|PubMed:16352559,
CC       ECO:0000269|PubMed:16816390}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, PML body
CC       {ECO:0000269|PubMed:11731474, ECO:0000269|PubMed:16816390}.
CC       Note=Colocalizes with SUMO1 and TCF7L2/TCF4 and LEF1 in a subset
CC       of PML (promyelocytic leukemia) nuclear bodies. Accumulates in the
CC       cytoplasm upon treatment with UVB and TNF-alpha.
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in
CC       testis. Also expressed in vascular endothelial cells, in primary
CC       keratinocytes and in the CNS, including cortex, olfactory bulb,
CC       spinal cord, thalamus and trigeminal ganglion. Low expression, if
CC       any, in liver and lung. {ECO:0000269|PubMed:10854042,
CC       ECO:0000269|PubMed:12750312}.
CC   -!- DEVELOPMENTAL STAGE: At 8.5 dpc, expressed primarily in the
CC       anterior part of the neural tube. At 10.5 dpc, expressed in the
CC       neuroepithelium of the forebrain and hindbrain. At 11.5 dpc,
CC       detected in the neural tube, eye, limb buds and brachial arches.
CC       At 12.5 dpc, expressed in the hindlimbs and forelimbs, as well as
CC       in the forebrain. At 12.5 and 13.5 dpc, detected in single cells
CC       in the marginal zone of the developing cortex, as well as in other
CC       developing tissues and organs. At 13.5 dpc, expressed in the
CC       developing limb buds, in single cells in the mesenchyme
CC       surrounding future digit structures. At 15.5 dpc, detected in the
CC       inner root sheath of vibrissa hair follicle. Expression in the
CC       inner root sheath of the hair follicle continues later in life as
CC       it can also be detected in the back skin of newborn at postnatal
CC       day 3. At 16.5 dpc, expressed in the epithelium of olfactory and
CC       in the retina. {ECO:0000269|PubMed:10854042}.
CC   -!- DOMAIN: The LXXLL motif is a coregulator signature that is
CC       essential for transcriptional corepression.
CC   -!- PTM: Sumoylated. Lys-35 is the main site of sumoylation.
CC       Sumoylation is required for TCF4 sumoylation and transcriptional
CC       activation. Represses LEF1 transcriptional activity. SUMO1 is the
CC       preferred conjugate. {ECO:0000269|PubMed:11731474}.
CC   -!- PTM: Ubiquitinated by TRIM32 upon treatment with UVB and TNF-
CC       alpha. {ECO:0000269|PubMed:16816390}.
CC   -!- SIMILARITY: Belongs to the PIAS family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   -----------------------------------------------------------------------
DR   EMBL; AF109174; AAF72040.1; -; mRNA.
DR   EMBL; BC025159; AAH25159.1; -; mRNA.
DR   CCDS; CCDS35992.1; -.
DR   RefSeq; NP_067476.2; NM_021501.4.
DR   UniGene; Mm.34428; -.
DR   ProteinModelPortal; Q9JM05; -.
DR   SMR; Q9JM05; -.
DR   BioGrid; 208475; 6.
DR   DIP; DIP-60971N; -.
DR   IntAct; Q9JM05; 2.
DR   STRING; 10090.ENSMUSP00000005064; -.
DR   iPTMnet; Q9JM05; -.
DR   PhosphoSitePlus; Q9JM05; -.
DR   EPD; Q9JM05; -.
DR   MaxQB; Q9JM05; -.
DR   PaxDb; Q9JM05; -.
DR   PRIDE; Q9JM05; -.
DR   Ensembl; ENSMUST00000005064; ENSMUSP00000005064; ENSMUSG00000004934.
DR   GeneID; 59004; -.
DR   KEGG; mmu:59004; -.
DR   UCSC; uc007ggc.3; mouse.
DR   CTD; 51588; -.
DR   MGI; MGI:2136940; Pias4.
DR   eggNOG; KOG2169; Eukaryota.
DR   eggNOG; ENOG410XQ2E; LUCA.
DR   GeneTree; ENSGT00550000074410; -.
DR   HOGENOM; HOG000230594; -.
DR   HOVERGEN; HBG053598; -.
DR   InParanoid; Q9JM05; -.
DR   KO; K16065; -.
DR   OMA; LRICYTD; -.
DR   OrthoDB; EOG091G08G5; -.
DR   PhylomeDB; Q9JM05; -.
DR   TreeFam; TF323787; -.
DR   Reactome; R-MMU-3108214; SUMOylation of DNA damage response and repair proteins.
DR   Reactome; R-MMU-3232118; SUMOylation of transcription factors.
DR   Reactome; R-MMU-3232142; SUMOylation of ubiquitinylation proteins.
DR   Reactome; R-MMU-4085377; SUMOylation of SUMOylation proteins.
DR   Reactome; R-MMU-4090294; SUMOylation of intracellular receptors.
DR   Reactome; R-MMU-4615885; SUMOylation of DNA replication proteins.
DR   Reactome; R-MMU-4755510; SUMOylation of immune response proteins.
DR   Reactome; R-MMU-5693565; Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks.
DR   Reactome; R-MMU-5693571; Nonhomologous End-Joining (NHEJ).
DR   Reactome; R-MMU-69473; G2/M DNA damage checkpoint.
DR   UniPathway; UPA00886; -.
DR   PRO; PR:Q9JM05; -.
DR   Proteomes; UP000000589; Chromosome 10.
DR   Bgee; ENSMUSG00000004934; Expressed in 263 organ(s), highest expression level in bone marrow.
DR   CleanEx; MM_PIAS4; -.
DR   ExpressionAtlas; Q9JM05; baseline and differential.
DR   Genevisible; Q9JM05; MM.
DR   GO; GO:0005737; C:cytoplasm; ISO:MGI.
DR   GO; GO:0016363; C:nuclear matrix; IDA:MGI.
DR   GO; GO:0005654; C:nucleoplasm; IDA:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0016605; C:PML body; IEA:UniProtKB-SubCell.
DR   GO; GO:1990234; C:transferase complex; IDA:BHF-UCL.
DR   GO; GO:0003677; F:DNA binding; IDA:MGI.
DR   GO; GO:0008022; F:protein C-terminus binding; ISO:MGI.
DR   GO; GO:0061665; F:SUMO ligase activity; IDA:BHF-UCL.
DR   GO; GO:0019789; F:SUMO transferase activity; IDA:MGI.
DR   GO; GO:0003714; F:transcription corepressor activity; IDA:MGI.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0008270; F:zinc ion binding; NAS:UniProtKB.
DR   GO; GO:0007259; P:JAK-STAT cascade; ISA:MGI.
DR   GO; GO:0007275; P:multicellular organism development; NAS:UniProtKB.
DR   GO; GO:0032088; P:negative regulation of NF-kappaB transcription factor activity; IDA:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:UniProtKB.
DR   GO; GO:0010804; P:negative regulation of tumor necrosis factor-mediated signaling pathway; IMP:MGI.
DR   GO; GO:1902231; P:positive regulation of intrinsic apoptotic signaling pathway in response to DNA damage; IDA:MGI.
DR   GO; GO:1902174; P:positive regulation of keratinocyte apoptotic process; IDA:BHF-UCL.
DR   GO; GO:0033235; P:positive regulation of protein sumoylation; ISS:UniProtKB.
DR   GO; GO:0016925; P:protein sumoylation; IDA:BHF-UCL.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   GO; GO:0016032; P:viral process; IEA:UniProtKB-KW.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.720.30; -; 1.
DR   Gene3D; 2.60.120.780; -; 1.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR027224; PIAS4.
DR   InterPro; IPR023321; PINIT.
DR   InterPro; IPR038654; PINIT_sf.
DR   InterPro; IPR003034; SAP_dom.
DR   InterPro; IPR036361; SAP_dom_sf.
DR   InterPro; IPR004181; Znf_MIZ.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   PANTHER; PTHR10782:SF9; PTHR10782:SF9; 1.
DR   Pfam; PF14324; PINIT; 1.
DR   Pfam; PF02891; zf-MIZ; 1.
DR   SMART; SM00513; SAP; 1.
DR   SUPFAM; SSF68906; SSF68906; 1.
DR   PROSITE; PS51466; PINIT; 1.
DR   PROSITE; PS50800; SAP; 1.
DR   PROSITE; PS51044; ZF_SP_RING; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; DNA-binding; Host-virus interaction;
KW   Isopeptide bond; Metal-binding; Nucleus; Reference proteome;
KW   Repressor; Transcription; Transcription regulation; Transferase;
KW   Ubl conjugation; Ubl conjugation pathway; Wnt signaling pathway; Zinc;
KW   Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CHAIN         2    507       E3 SUMO-protein ligase PIAS4.
FT                                /FTId=PRO_0000218983.
FT   DOMAIN       12     46       SAP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00186, ECO:0000305}.
FT   DOMAIN      112    272       PINIT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00799}.
FT   ZN_FING     304    381       SP-RING-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00452}.
FT   MOTIF        20     24       LXXLL motif.
FT   COMPBIAS    462    488       Asp/Glu-rich (acidic).
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   MOD_RES     107    107       N6-acetyllysine.
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK      9      9       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK     35     35       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate. {ECO:0000250}.
FT   CROSSLNK     35     35       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2);
FT                                alternate.
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK     56     56       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK     59     59       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK     68     68       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK     69     69       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK    118    118       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000250|UniProtKB:Q8N2W9}.
FT   CROSSLNK    128    128       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000250}.
FT   MUTAGEN     330    330       C->S: Abrogates sumoylation of LEF1 and
FT                                increases LEF1-mediated transcriptional
FT                                activity; when associated with S-335; A-
FT                                337 and S-340.
FT                                {ECO:0000269|PubMed:11731474}.
FT   MUTAGEN     335    335       C->S: Abrogates sumoylation of LEF1 and
FT                                increases LEF1-mediated transcriptional
FT                                activity; when associated with S-330; A-
FT                                337 and S-340.
FT                                {ECO:0000269|PubMed:11731474}.
FT   MUTAGEN     337    337       H->A: Abrogates sumoylation of LEF1 and
FT                                increases LEF1-mediated transcriptional
FT                                activity; when associated with S-330; S-
FT                                335 and S-340.
FT                                {ECO:0000269|PubMed:11731474}.
FT   MUTAGEN     340    340       C->S: Abrogates sumoylation of LEF1 and
FT                                increases LEF1-mediated transcriptional
FT                                activity; when associated with S-330; S-
FT                                335 and A-337.
FT                                {ECO:0000269|PubMed:11731474}.
FT   MUTAGEN     470    474       SSSSS->AAAAA: No effect on sumoylation of
FT                                LEF1, nor on LEF1-binding.
FT                                {ECO:0000269|PubMed:11731474}.
FT   CONFLICT    230    230       K -> N (in Ref. 1; AAF72040).
FT                                {ECO:0000305}.
FT   CONFLICT    417    417       L -> H (in Ref. 1; AAF72040).
FT                                {ECO:0000305}.
FT   CONFLICT    494    494       K -> N (in Ref. 1; AAF72040).
FT                                {ECO:0000305}.
SQ   SEQUENCE   507 AA;  55570 MW;  A8E5E6E3BAC76426 CRC64;
     MAAELVEAKN MVMSFRVSDL QMLLGFVGRS KSGLKHELVT RALQLVQFDC SPELFKKIKE
     LYETRYAKKS AEPGPQAPRP LDPLALHSMP RTPLSGPTVD YPVLYGKYLN GLGRLPTKTL
     KPEVRLVKLP FFNMLDELLK PTELVPQSAE KLQESPCIFA LTPRQVEMIR NSRELQPGVK
     AVQVVLRICY SDTSCPQEDQ YPPNIAVKVN HSYCSVPGYY PSNKPGVEPK RPCRPINLTH
     LMYLSSATNR ITVTWGNYGK SYSVALYLVR QLTSSDLLQR LKTIGVKHPE LCKALVKEKL
     RLDPDSEIAT TGVRVSLICP LVKMRLSVPC RAETCAHLQC FDAVFYLQMN EKKPTWMCPV
     CDKPAAYDQL IIDGLLSKIL SECEGADEIE FLAEGSWRPI RAEKEPSCSP QGPILVLGTS
     DANGLAPASS TPGIGSGLSG PGSAGSGAGA AGSLENGKTG ADVVDLTLDS SSSSEDEDED
     EDDDEDEDEG PRPKRRCPFQ KGLVPAC
//
